Advertisement
Advertisement
U.S. markets close in 5 hours 42 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Tryp Therapeutics Inc. (TRYPF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1885+0.0068 (+3.74%)
As of 09:46AM EST. Market open.
Advertisement

Tryp Therapeutics Inc.

1665 Ellis Street
Suite 301
Kelowna, BC V1Y 2B3
Canada

https://www.tryptherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Gregory M. McKee M.B.A., M.A., MBAExec. Chairman & CEON/AN/A1964
Dr. James P. GilliganPres & Chief Scientific OfficerN/AN/A1952
Mr. Luke HayesChief Financial OfficerN/AN/AN/A
Mr. Thomas D'Orazio B.Sc., M.B.A.Chief Operating OfficerN/AN/AN/A
Ms. Joy WillisDirector of Investor RelationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tryp Therapeutics Inc., a clinical stage pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases. The company's lead development program is psilocybin-for-neuropsychiatry (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 for fibromyalgia, hyperphagia in prader-willi syndrome, and other therapies; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. Tryp Therapeutics Inc. has an agreement with the University of Michigan to perform research related to its psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was founded in 2019 and is headquartered in Kelowna, Canada.

Corporate Governance

Tryp Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement